First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. Presented at: ASCO-GU ...

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced ...

In the lenvatinib–pembrolizumab group, patients received lenvatinib at a dose of 20 mg, administered orally once daily, plus pembrolizumab at a dose of 200 mg, administered intravenously as a 30 ...

Lenvatinib, an antiangiogenic agent, and pembrolizumab, an anti–programmed cell death 1 (PD-1) monoclonal antibody, have each shown activity as monotherapies for the treatment of renal cell ...

Lenvatinib plus pembrolizumab improved outcomes vs. chemotherapy for women with advanced endometrial cancer, according to findings presented at the virtual Society of Gynecologic Oncology Annual ...

The LEAP-004 safety profile was generally consistent with that previously observed for lenvatinib plus pembrolizumab in other tumor types. 17-21 The lower incidence of grade 3-5 treatment-related AEs ...

WOODCLIFF LAKE, N.J., Sept. 10, 2017 /PRNewswire/ -- Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating ...

Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORR ...

Pembrolizumab plus lenvatinib prolonged survival compared with sunitinib among patients with previously untreated renal cell carcinoma.

Updated results from the CLEAR trial suggest that lenvatinib and pembrolizumab can provide durable benefits over sunitinib in patients with treatment-naïve, advanced renal cell carcinoma (RCC).

Source Reference: Llovet JM, et al "Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial" Lancet ...